The AML‐MRC ASXL1+ cases were predominantly patients with a previous history of MDS or MDS/MPN: 14 of 19 (73.7%) with previous MDS or MDS/MPN in ASXL1+ as compared to 11 out of 42 (26.2%) in AML‐MRC ASXL1− patients, P < .001. This evidence concerns the gene CD200 and myeloproliferative neoplasm.